Showing results (61-70 of 111) with videos related to
Sort By:
Pageof 12
International Journal of Clinical Pharmacology and Therapeutics|November 15, 2016
Utilization of population pharmacokinetics in drug development and provision of the results to healthcare professionals
Megumi Watanabe-Uchida, Mamoru NarukawaPharmacoepidemiology and Drug Safety|August 11, 2018
Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugsJunji Ikeda, Masayuki Kaneko, Mamoru NarukawaClinical Drug Investigation|June 29, 2019
Meta-analysis of Dropout Rates in Placebo-Controlled Randomized Clinical Trials of Atypical Antipsychotics Assessed by PANSSAkiko Matsusaki, Masayuki Kaneko, Mamoru NarukawaClinical and Translational Science|April 8, 2021
Approval success rates of drug candidates based on target, action, modality, application, and their combinationsShingo Yamaguchi, Masayuki Kaneko, Mamoru NarukawaInternational Journal of Clinical Oncology|January 18, 2020
Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancerYosuke Yoshida, Masayuki Kaneko, Mamoru NarukawaClinical Drug Investigation|January 7, 2015
An investigation of factors contributing to higher levels of placebo response in clinical trials in neuropathic pain: a systematic review and meta-analysisAkio Arakawa, Masayuki Kaneko, Mamoru NarukawaLower Urinary Tract Symptoms|October 30, 2016
Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature ReviewShingo Iino, Masayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|March 3, 2021
Predictability of Severe Adverse Events in Phase 3 Trials from Safety Information on Phase 1 Trials in Oncology Drug DevelopmentTakashi Sawada, Masayuki Kaneko, Mamoru NarukawaJournal of Biopharmaceutical Statistics|June 23, 2004
Observation of time-dependent adverse events and the influence of drop-out thereon in long-term safety studies--simulation study under the current practice of post-marketing safety evaluation in JapanMamoru Narukawa, Akifumi Yafune, Masahiro TakeuchiTumori|April 25, 2015
Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancerMasato Komuro, Masayuki Kaneko, Mamoru NarukawaPageof 12